Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (1191)	5/26/2000 9:06:00 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 4474

By sheer coincidence, The IHGT (Penn) made this stunning announcement Wednesday - med.upenn.edu Action #2 is unbelievable - IHGT TO DISCONTINUE CLINICAL TRIALS TO FOCUS ON BASIC SCIENCE, ANIMAL MODELS AND PRE-CLINICAL WORK No more trials means the 'raison d'etre' of the institute is toast! There's a helluva lot of commentary that could be scribbled here...but, in the context of this discussion, this is PRECISELY what can happen when arrogant and self-righteous scientists (I should know) feel oversight is a burden and therefore can clinical procedure can be left to their own discretion. As predicted 6 months ago, Wilson's career is probably over. In a similar vein, immediately following Gelsinger's death, there was a minority of folks (including yours truly) who STRONGLY requested that Ariad make a public statement regarding their ongoing collaboration with Wilson. There was also some sentiment that they should begin to look elsewhere for GT. Now what are you going to do Ariad, eh? I can't HEAR you.